Abstract

Mucormycosis is a common pathogen infecting acute lymphoblastic leukemia patients in bone marrow suppression period after chemotherapy. Infection of mucormycosis on skin is relatively rare. In this study, we present a 7-year-old boy diagnosed as acute lymphoblastic leukemia with myeloid expression and mucormycosis infection on skin. Cutaneous mucormycosis occurred on the right forearm after chemotherapy with increasing manifestations of recurrent fever, local skin necrosis and eschar, skin temperature elevation, and swelling painful feeling of right forearm. Tissue smear examination and cell culture results showed that the patient was with mucormycosis infection. Local debridement was carried out and amphotericin B applied for anti-fungal infection treatment. Although constitutional symptom was controlled after anti-infection therapy, surrounding muscles that were affected by the local necrosis kept getting worse. Therefore, free flap transplantation was undertaken along with surgical debridement, and the patient was cured with right hand function preserved completely. Follow-up examination showed that the child entered the maintain chemotherapy stage for leukemia and the local skin was growing well without infection again. In summary, our result indicated that although mucormycosis is hazardous and fatal, early detection and treatment can significantly reduce the mortality whereas drug therapy combined with surgical treatment could further enhance the cure rate.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.